FONT-SIZE Plus   Neg

Ironwood, Bionomics Collaborate On Anti-Anxiety Compound BNC210 - Quick Facts

Ironwood Pharmaceuticals Inc. (IRWD) and Australia-based Bionomics Limited Wednesday entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics' investigational anti-anxiety compound BNC210 and other related compounds.

According to the companies, the aim of collaboration is to assess the compound's potential as a novel anti-anxiety treatment. Data from several preclinical studies indicate that BNC210 has anti-anxiety activity without the sedative side effects that are typical of benzodiazepines, a class of drugs used to treat anxiety, they said.

As per the terms, the companies will collaborate on initial research, and Massachusetts-based Ironwood will be responsible for worldwide development and commercialization of all products incorporating BNC210 or other licensed compounds, including funding of clinical trials.

The companies said that pending achievement of certain development and regulatory milestones, Bionomics could receive up to US$345 million in upfront and milestone payments and research funding, as well as royalties on sales of products incorporating BNC210 and other related compounds.

Over the next 24 months, Bionomics may receive up to US$13 million in research funding and milestone payments, including an initial payment of US$3 million.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Baker Hughes Inc.'s shares gained around 7 percent in the extended trading on Thursday after conglomerate General Electric Co. confirmed, while responding to media reports, that it is in talks to buy the oilfield services provider. The stock is moving 6 percent ahead in the pre-market activity. Shares of Sanofi were gaining around 7 percent in the morning trading in Paris after the French drug maker on Friday raised its 2016 business earnings guidance, after it reported strong third-quarter results. In addition, the company set a 3.5 billion euros share repurchase program to be completed by the end of 2017. Swiss banking giant UBS Group AG (UBS) reported Friday an increased pre-tax profit for the third quarter despite weakness in net interest income. Net profit, however, decreased on the absence of last year's hefty tax benefit. Looking ahead, UBS said it is unlikely that the underlying macroeconomic uncertainty and geopolitical tensions will change in the foreseeable future.
comments powered by Disqus
Follow RTT